159 related articles for article (PubMed ID: 37184523)
1. Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
Bowlus CL; Eksteen B; Cheung AC; Thorburn D; Moylan CA; Pockros PJ; Forman LM; Dorenbaum A; Hirschfield GM; Kennedy C; Jaecklin T; McKibben A; Chien E; Baek M; Vig P; Levy C
Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37184523
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
Gonzales E; Hardikar W; Stormon M; Baker A; Hierro L; Gliwicz D; Lacaille F; Lachaux A; Sturm E; Setchell KDR; Kennedy C; Dorenbaum A; Steinmetz J; Desai NK; Wardle AJ; Garner W; Vig P; Jaecklin T; Sokal EM; Jacquemin E
Lancet; 2021 Oct; 398(10311):1581-1592. PubMed ID: 34755627
[TBL] [Abstract][Full Text] [Related]
3. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Miethke AG; Moukarzel A; Porta G; Covarrubias Esquer J; Czubkowski P; Ordonez F; Mosca A; Aqul AA; Squires RH; Sokal E; D'Agostino D; Baumann U; D'Antiga L; Kasi N; Laborde N; Arikan C; Lin CH; Gilmour S; Mittal N; Chiou FK; Horslen SP; Huber WD; Jaecklin T; Nunes T; Lascau A; Longpre L; Mogul DB; Garner W; Vig P; Hupertz VF; Gonzalez-Peralta RP; Ekong U; Hartley J; Laverdure N; Ovchinsky N; Thompson RJ
Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):620-631. PubMed ID: 38723644
[TBL] [Abstract][Full Text] [Related]
4. Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study.
Loomes KM; Squires RH; Kelly D; Rajwal S; Soufi N; Lachaux A; Jankowska I; Mack C; Setchell KDR; Karthikeyan P; Kennedy C; Dorenbaum A; Desai NK; Garner W; Jaecklin T; Vig P; Miethke A; Thompson RJ
Hepatol Commun; 2022 Sep; 6(9):2379-2390. PubMed ID: 35507739
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.
Mayo MJ; Pockros PJ; Jones D; Bowlus CL; Levy C; Patanwala I; Bacon B; Luketic V; Vuppalanchi R; Medendorp S; Dorenbaum A; Kennedy C; Novak P; Gu J; Apostol G; Hirschfield GM
Hepatol Commun; 2019 Mar; 3(3):365-381. PubMed ID: 30859149
[TBL] [Abstract][Full Text] [Related]
6. Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review.
Smith HT; de Souza AR; Thompson AH; McLaughlin MM; Dever JJ; Myers JA; Chen JV
Dig Dis Sci; 2023 Jun; 68(6):2710-2730. PubMed ID: 36933112
[TBL] [Abstract][Full Text] [Related]
7. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
Baumann U; Sturm E; Lacaille F; Gonzalès E; Arnell H; Fischler B; Jørgensen MH; Thompson RJ; Mattsson JP; Ekelund M; Lindström E; Gillberg PG; Torfgård K; Soni PN
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101751. PubMed ID: 34182185
[TBL] [Abstract][Full Text] [Related]
8. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
9. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
10. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
11. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.
Al-Dury S; Wahlström A; Wahlin S; Langedijk J; Elferink RO; Ståhlman M; Marschall HU
Sci Rep; 2018 Apr; 8(1):6658. PubMed ID: 29704003
[TBL] [Abstract][Full Text] [Related]
12. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
13. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
[No Abstract] [Full Text] [Related]
15. Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome.
Shneider BL; Spino CA; Kamath BM; Magee JC; Ignacio RV; Huang S; Horslen SP; Molleston JP; Miethke AG; Kohli R; Leung DH; Jensen MK; Loomes KM; Karpen SJ; Mack C; Rosenthal P; Squires RH; Baker A; Rajwal S; Kelly D; Sokol RJ; Thompson RJ;
Hepatol Commun; 2022 Aug; 6(8):1922-1933. PubMed ID: 35672955
[TBL] [Abstract][Full Text] [Related]
16. Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency.
Zhao X; Zhang W; Vig P; Kostrub C; Setchell KDR
Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295854
[TBL] [Abstract][Full Text] [Related]
17. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
20. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.
Kuiper EM; van Erpecum KJ; Beuers U; Hansen BE; Thio HB; de Man RA; Janssen HL; van Buuren HR
Hepatology; 2010 Oct; 52(4):1334-40. PubMed ID: 20683930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]